Bank of Queensland Ltd (ASX: BOQ), Telix Pharmaceuticals Ltd (ASX: TLX), and NextDC Ltd (ASX: NXT) shares are grabbing headlines today.
In late morning trade on Tuesday, all three blue-chip stocks are racing ahead of the 2.6% intraday gains posted by the S&P/ASX 200 Index (ASX: XJO).
Here’s what’s happening.
NextDC shares leap on $1 billion funding news
Turning to NextDC first, shares in the ASX 200 data centre operator and developer are up 13.6% today, trading for $12.79 apiece.
Investors are sending NextDC shares surging after the company announced it was raising $1 billion in new funds via the issue of new hybrid securities.
The hybrid securities launch is backed by Canadian investment group La Caisse, which inked a binding $1 billion commitment to make up for any potential shortfall.
The securities carry a 100-year maturity.
The new funds will support NextDC’s plans to develop new data centres and expand capacity.
Commenting on the fund-raising initiative that’s boosting NextDC shares today, CEO Craig Scroggie said:
The announcement of the Hybrid Securities Offer and the La Caisse commitment represent another step toward NextDC delivering on a material step-change in the scale of our business as we deliver on the company’s contracted forward order book across the period to FY29 and make further investments across the portfolio of new projects.
Which brings us toâ¦
Telix shares surge on revenue growth
Telix shares are also catching plenty of investor attention today.
Shares in the ASX 200 diagnostic and therapeutic product developer are up 6.3% today, trading for $13.77 each.
This follows the release of Telix’s March quarterly update.
Among the highlights, the company reported an 11% quarter-on-quarter increase in unaudited revenue to US$230 million. And management reaffirmed full-year FY 2026 revenue guidance in the range of US$950 million to US$970 million.
The March quarter saw the ASX healthcare share continue to advance its global studies across prostate, brain, and kidney cancer.
“We are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter,” Telix CEO Christian Behrenbruch said.
Bank of Queensland shares jump on strategic loan sale
Last, but not least, Bank of Queensland shares join Telix and NextDC shares in grabbing financial headlines and outperforming today.
Shares in the ASX 200 bank stock are up 5.3% at the time of writing, changing hands for $7.16 each.
Investors are bidding up Bank of Queensland shares after the company reported on its $3.7 billion equipment finance loan sale to investment management firm Challenger Ltd (ASX: CGF).
Why is this boosting the Bank of Queensland share price today?
As the Motley Fool reported this morning:
The capital partnership enables BOQ to accelerate its specialist banking transformation by shifting equipment finance exposures off balance sheet while growing capital-light revenues. The transition is designed to improve return on equity and support further business in the small and medium business sector.
The post Why is everyone talking about Telix, Bank of Queensland and NextDC shares today? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Bank of Queensland right now?
Before you buy Bank of Queensland shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Bank of Queensland wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- ASX 200 surging as investors look beyond Iran war
- Why are Telix shares jumping 8% today?
- Why are NextDC shares surging higher?
- Bank of Queensland announces $3.7bn loan sale and capital partnership with Challenger
- NEXTDC announces $1 billion hybrid securities offer and La Caisse backing
Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Challenger and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.